# American Healthcare REIT, Inc.: financial statements, quarterly

AHR · NYSE · CIK 1632970 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ahr.md) · [Financials](/companies/ahr/financials.md) · [Filings](/companies/ahr/filings.md) · [Insiders](/companies/ahr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ahr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [416](/filings/0001632970-24-000121.md) | [433 d](/filings/0001193125-26-082692.md) | [452](/filings/0001632970-25-000042.md) | [458](/filings/0001632970-25-000064.md) | [477](/filings/0001193125-25-272390.md) | [497 d](/filings/0001193125-26-082692.md) | [497](/filings/0001193125-26-214678.md) | [501](/filings/0001193125-26-340269.md) | [532](/filings/0001193125-25-272390.md) | [564 d](/filings/0001193125-26-082692.md) | [610](/filings/0001193125-26-214678.md) | [635](/filings/0001193125-26-340269.md) |
| Cost of revenue | $m | [375](/filings/0001632970-24-000121.md) | [385 d](/filings/0001193125-26-082692.md) | [404](/filings/0001632970-25-000042.md) | [403](/filings/0001632970-25-000064.md) | [417](/filings/0001193125-25-272390.md) | [431 d](/filings/0001193125-26-082692.md) | [432](/filings/0001193125-26-214678.md) | [426](/filings/0001193125-26-340269.md) | [455](/filings/0001193125-25-272390.md) | [480 d](/filings/0001193125-26-082692.md) | [512](/filings/0001193125-26-214678.md) | [525](/filings/0001193125-26-340269.md) |
| Operating income | $m | [75.1](/filings/0001632970-24-000121.md) | [84.5 d](/filings/0001193125-26-082692.md) | [82.2](/filings/0001632970-25-000042.md) | [88.7](/filings/0001632970-25-000064.md) | [93.5](/filings/0001193125-25-272390.md) | [99.1 d](/filings/0001193125-26-082692.md) | [94.5](/filings/0001193125-26-214678.md) | [103](/filings/0001193125-26-340269.md) | [106](/filings/0001193125-25-272390.md) | [112 d](/filings/0001193125-26-082692.md) | [126](/filings/0001193125-26-214678.md) | [137](/filings/0001193125-26-340269.md) |
| Interest expense | $m | [42.0](/filings/0001632970-24-000121.md) | [41.2 d](/filings/0001193125-26-082692.md) | [36.4](/filings/0001632970-25-000042.md) | [30.6](/filings/0001632970-25-000064.md) | [30.4](/filings/0001193125-25-272390.md) | [30.3 d](/filings/0001193125-26-082692.md) | [22.9](/filings/0001193125-26-214678.md) | [22.6](/filings/0001193125-26-340269.md) | [20.4](/filings/0001193125-25-272390.md) | [19.8 d](/filings/0001193125-26-082692.md) | [18.8](/filings/0001193125-26-214678.md) | [18.6](/filings/0001193125-26-340269.md) |
| Income tax | $m | [0.3](/filings/0001632970-24-000121.md) | [(0.1) d](/filings/0001193125-26-082692.md) | [0.3](/filings/0001632970-25-000042.md) | [0.7](/filings/0001632970-25-000064.md) | [0.3](/filings/0001193125-25-272390.md) | [0.5 d](/filings/0001193125-26-082692.md) | [0.6](/filings/0001193125-26-214678.md) | [0.7](/filings/0001193125-26-340269.md) | [(21.1)](/filings/0001193125-25-272390.md) | [(2.4) d](/filings/0001193125-26-082692.md) | [(0.5)](/filings/0001193125-26-214678.md) | [(0.0)](/filings/0001193125-26-340269.md) |
| Net income | $m | [(6.0)](/filings/0001632970-24-000121.md) | [(27.4) d](/filings/0001193125-26-082692.md) | [(3.9)](/filings/0001632970-25-000042.md) | [2.0](/filings/0001632970-25-000064.md) | [(4.1)](/filings/0001193125-25-272390.md) | [(31.8) d](/filings/0001193125-26-082692.md) | [(6.8)](/filings/0001193125-26-214678.md) | [9.9](/filings/0001193125-26-340269.md) | [55.9](/filings/0001193125-25-272390.md) | [10.8 d](/filings/0001193125-26-082692.md) | [23.7](/filings/0001193125-26-214678.md) | [30.6](/filings/0001193125-26-340269.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001632970-24-000121.md) | not reported | [(0.04)](/filings/0001632970-25-000042.md) | [0.01](/filings/0001632970-25-000064.md) | [(0.03)](/filings/0001193125-25-272390.md) | not reported | [(0.04)](/filings/0001193125-26-214678.md) | [0.06](/filings/0001193125-26-340269.md) | [0.33](/filings/0001193125-25-272390.md) | not reported | [0.13](/filings/0001193125-26-214678.md) | [0.16](/filings/0001193125-26-340269.md) |
| Basic EPS | $ per share | [(0.09)](/filings/0001632970-24-000121.md) | not reported | [(0.04)](/filings/0001632970-25-000042.md) | [0.01](/filings/0001632970-25-000064.md) | [(0.03)](/filings/0001193125-25-272390.md) | not reported | [(0.04)](/filings/0001193125-26-214678.md) | [0.06](/filings/0001193125-26-340269.md) | [0.33](/filings/0001193125-25-272390.md) | not reported | [0.13](/filings/0001193125-26-214678.md) | [0.16](/filings/0001193125-26-340269.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [35.2](/filings/0001632970-24-000121.md) | [43.4](/filings/0001193125-26-082692.md) | [77.0](/filings/0001632970-25-000042.md) | [52.1](/filings/0001632970-25-000064.md) | [67.9](/filings/0001193125-25-272390.md) | [76.7](/filings/0001193125-26-340269.md) | [86.1](/filings/0001193125-26-214678.md) | [133](/filings/0001193125-26-340269.md) | [147](/filings/0001193125-25-272390.md) | [115](/filings/0001193125-26-340269.md) | [119](/filings/0001193125-26-214678.md) | [157](/filings/0001193125-26-340269.md) |
| Total assets | $m | [4,589](/filings/0001632970-23-000101.md) | [4,578](/filings/0001632970-25-000018.md) | [4,703](/filings/0001632970-24-000057.md) | [4,645](/filings/0001632970-24-000085.md) | [4,677](/filings/0001632970-24-000121.md) | [4,488](/filings/0001193125-26-082692.md) | [4,464](/filings/0001632970-25-000042.md) | [4,507](/filings/0001632970-25-000064.md) | [4,770](/filings/0001193125-25-272390.md) | [5,426](/filings/0001193125-26-340269.md) | [5,599](/filings/0001193125-26-214678.md) | [5,704](/filings/0001193125-26-340269.md) |
| Total liabilities | $m | [3,055](/filings/0001632970-23-000101.md) | [3,119](/filings/0001632970-25-000018.md) | [2,561](/filings/0001632970-24-000057.md) | [2,541](/filings/0001632970-24-000085.md) | [2,420](/filings/0001632970-24-000121.md) | [2,184](/filings/0001193125-26-082692.md) | [2,159](/filings/0001632970-25-000042.md) | [2,044](/filings/0001632970-25-000064.md) | [2,050](/filings/0001193125-25-272390.md) | [2,066](/filings/0001193125-26-340269.md) | [2,077](/filings/0001193125-26-214678.md) | [1,962](/filings/0001193125-26-340269.md) |
| Shareholders' equity | $m | [1,314](/filings/0001632970-23-000101.md) | [1,270](/filings/0001632970-25-000018.md) | [1,961](/filings/0001632970-24-000057.md) | [1,933](/filings/0001632970-24-000085.md) | [2,207](/filings/0001632970-24-000121.md) | [2,261](/filings/0001193125-26-082692.md) | [2,262](/filings/0001632970-25-000042.md) | [2,421](/filings/0001632970-25-000064.md) | [2,678](/filings/0001193125-25-272390.md) | [3,321](/filings/0001193125-26-340269.md) | [3,482](/filings/0001193125-26-214678.md) | [3,695](/filings/0001193125-26-340269.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [29.1 d](/filings/0001632970-24-000121.md) | [25.8 d](/filings/0001193125-26-082692.md) | [(6.0)](/filings/0001632970-25-000042.md) | [59.4 d](/filings/0001632970-25-000064.md) | [63.1 d](/filings/0001193125-25-272390.md) | [59.5 d](/filings/0001193125-26-082692.md) | [60.6](/filings/0001193125-26-214678.md) | [71.5 d](/filings/0001193125-26-340269.md) | [107 d](/filings/0001193125-25-272390.md) | [55.2 d](/filings/0001193125-26-082692.md) | [81.1](/filings/0001193125-26-214678.md) | [119 d](/filings/0001193125-26-340269.md) |
| Dividends paid | $m | [16.6 d](/filings/0001632970-24-000121.md) | [16.6 d](/filings/0001193125-26-082692.md) | [16.6](/filings/0001632970-25-000042.md) | [33.0 d](/filings/0001632970-25-000064.md) | [33.0 d](/filings/0001193125-25-272390.md) | [38.3 d](/filings/0001193125-26-082692.md) | [39.5](/filings/0001193125-26-214678.md) | [39.9 d](/filings/0001193125-26-340269.md) | [41.2 d](/filings/0001193125-25-272390.md) | [42.9 d](/filings/0001193125-26-082692.md) | [46.8](/filings/0001193125-26-214678.md) | [47.6 d](/filings/0001193125-26-340269.md) |
| Share repurchases | $m | [0.0 d](/filings/0001632970-24-000121.md) | [0.3 d](/filings/0001193125-26-082692.md) | [0.0](/filings/0001632970-25-000042.md) | [0.0 d](/filings/0001632970-25-000064.md) | [0.0 d](/filings/0001193125-25-272390.md) | [0.0 d](/filings/0001193125-26-082692.md) | [0.0](/filings/0001632970-25-000042.md) | [0.0 d](/filings/0001632970-25-000064.md) | [0.0 d](/filings/0001193125-25-272390.md) | [0.0 d](/filings/0001193125-26-082692.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [65.8](/filings/0001632970-23-000101.md) | [66.0](/filings/0001632970-24-000057.md) | [66.0](/filings/0001632970-24-000085.md) | [66.0](/filings/0001632970-24-000121.md) | [104](/filings/0001632970-25-000042.md) | [131](/filings/0001632970-25-000064.md) | [134](/filings/0001193125-25-272390.md) | [157](/filings/0001193125-26-214678.md) | [161](/filings/0001193125-26-340269.md) | [170](/filings/0001193125-25-272390.md) | [188](/filings/0001193125-26-214678.md) | [193](/filings/0001193125-26-340269.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 217,998,775 at 2026-08-03, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-340269.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.